

Attachment C



[Home](#) > [About FDA](#) > [Transparency](#) > [FDA-TRACK: Agency-wide Program Performance](#)

About FDA

May 24, 2011: FDA-TRACK Advisory Committees Quarterly Briefing Summary

✉ [Sign up to receive FDA-TRACK email updates](#)¹

Advisory Committees Dashboard²

- In the last 12 months, the FDA advisory committee vacancy rate has been reduced from 34% to 23%. During this time, 71 net advisory committee positions were filled.
- FDA has 49 advisory committees and panels and held 18 advisory committee meetings in FY 2011 Q2. For more information about upcoming FDA advisory committee meetings please see the advisory committee calendar website: <http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>³.
- FDA advisory committee staffs reported on several successful outreach events in FY 2011 including posting notices in the Federal Register, meeting with professional organizations, and participating in conferences. FDA receives an average of 57 nominations per month from individuals interested in becoming members of FDA's advisory committees. Additional information about [vacancies on advisory committees](#)⁴ and the [nomination process](#)⁵ can be found on the FDA website.
- FDA product Centers reported having several nomination packages in the final stages of the clearance and review process. The [Center for Devices and Radiological Health \(CDRH\)](#)⁶ reported that 15 nominations are in the clearance process to fill vacancies on the [Technical Electronic Product Radiation Standards Advisory Committee](#)⁷. This committee advises FDA about proposed performance standards for electronic products which emit radiation. The [Center for Drug Evaluation and Research \(CDER\)](#)⁸ and the [Center for Biologics Evaluation and Research \(CBER\)](#)⁹ reported that nine and three nomination packages, respectively, are also in the clearance process to fill vacancies on multiple CDER and CBER committees. Each of these packages contains multiple individual nominations. Nominees have been identified to fill seven of the eight current vacancies on the [Science Board to the Food and Drug Administration](#)¹⁰.
- Approximately 20 appointments will be made over the next couple of months for Consumer Representatives, who historically take longer to recruit due to their unique role in understanding scientific data while representing the voice of the consumer.

Contact Us

- **FDA-TRACK**
- FDATRACK@fda.hhs.gov
FDA-TRACK Team
OC/OPP/Office of Planning
10903 New Hampshire Avenue
WO32 - Rm. 3357
Silver Spring, MD 20993

Links on this page:

1. javascript:window.open('http://service.govdelivery.com/service/subscribe.html?code=USFDA_180','Popup','width=780, height=440, toolbar=no, scrollbars=yes, resizable=yes'); void("");
2. /AboutFDA/Transparency/track/ucm216403.htm
3. <http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>
4. /AdvisoryCommittees/AboutAdvisoryCommittees/CommitteeMembership/AdvisoryCommitteeVacancies/default.htm
5. /AdvisoryCommittees/AboutAdvisoryCommittees/CommitteeMembership/ApplyingforMembership/default.htm
6. /AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/default.htm
7. /AdvisoryCommittees/CommitteesMeetingMaterials/Radiation-EmittingProducts/TechnicalElectronicProductRadiationSafetyStandardsCommittee/default.htm
8. /AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/default.htm
9. /AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/default.htm
10. /AdvisoryCommittees/CommitteesMeetingMaterials/ScienceBoardtotheFoodandDrugAdministration/default.htm

About FDA

Home > About FDA > Transparency > FDA-TRACK: Agency-wide Program Performance

Browse FDA-TRACK Program Areas or Advisory Committees Index


Percent of FDA advisory committee member positions vacant at the end of the month

Download XML file | Related Links

Dictionary: Access to state-of-the-art, scientific expert advice to support agency decision making processes is imperative to the FDA advisory committee process. Having the fewest vacancies on our committees allows the agency to have ready access to those experts and supports the ability of FDA to meet its public health mission. For more information about FDA advisory committees, please visit <http://www.fda.gov/AdvisoryCommittees/default.htm>

Change Fiscal Year All

Change chart type: [Bar] [Line] [Area] [Pie]



Overlay measure(s):


- Number of FDA advisory committee member positions vacant at the end of the month
- Total number of FDA advisory committee member positions at the end of the month

Time	Target	Percent Vacant Positions
Oct 2009	10	33
Nov 2009	10	36
Dec 2009	10	TBD
Jan 2010	10	TBD
Feb 2010	10	35
Mar 2010	10	36
Apr 2010	10	34
May 2010	10	33
Jun 2010	10	31
Jul 2010	10	35
Aug 2010	10	29
Sep 2010	10	26
Oct 2010	10	25
Nov 2010	10	23
Dec 2010	10	23
Jan 2011	10	25
Feb 2011	10	23
Mar 2011	10	23
Apr 2011	N/A	TBD
May 2011	N/A	TBD
Jun 2011	N/A	TBD
Jul 2011	N/A	TBD
Aug 2011	N/A	TBD
Sep 2011	N/A	TBD

Number of FDA advisory committee member positions vacant at the end of the month



Total number of FDA advisory committee member positions at the end of the month



Time	Target	Vacant Positions
Oct 2009	N/A	199
Nov 2009	N/A	219
Dec 2009	N/A	TBD
Jan 2010	N/A	TBD
Feb 2010	N/A	213
Mar 2010	N/A	216
Apr 2010	N/A	209
May 2010	N/A	199
Jun 2010	N/A	189
Jul 2010	N/A	210
Aug 2010	N/A	177
Sep 2010	N/A	157
Oct 2010	N/A	155
Nov 2010	N/A	141
Dec 2010	N/A	140
Jan 2011	N/A	151
Feb 2011	N/A	139
Mar 2011	N/A	138
Apr 2011	N/A	TBD
May 2011	N/A	TBD
Jun 2011	N/A	TBD
Jul 2011	N/A	TBD
Aug 2011	N/A	TBD
Sep 2011	N/A	TBD

Time	Target	Positions
Oct 2009	N/A	608
Nov 2009	N/A	608
Dec 2009	N/A	TBD
Jan 2010	N/A	TBD
Feb 2010	N/A	608
Mar 2010	N/A	608
Apr 2010	N/A	608
May 2010	N/A	608
Jun 2010	N/A	608
Jul 2010	N/A	608
Aug 2010	N/A	608
Sep 2010	N/A	608
Oct 2010	N/A	608
Nov 2010	N/A	608
Dec 2010	N/A	608
Jan 2011	N/A	608
Feb 2011	N/A	608
Mar 2011	N/A	608
Apr 2011	N/A	608
May 2011	N/A	608
Jun 2011	N/A	608
Jul 2011	N/A	608
Aug 2011	N/A	608
Sep 2011	N/A	608

Related Links

- FDA-TRACK Advisory Committees Dashboard

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time.